ONCO
****Issuer Sponsored Content by TD Media, LLC
From Clinical Diagnostics to AI Robotics Exposure: Why Onconetix (NASDAQ: ONCO) Is Emerging as One of the Market’s Most Unexpected Multi-Theme Microcap Stories!
Onconetix Highlights Realbotix’s Launch of Humanoid Robot and AI Teachers Assistant Pilot Program in New York State School District
_________________________
Hello Everyone,
Onconetix (NASDAQ: ONCO) is shaping up to be one of the more compelling small-cap stories heading into today's session, and there are several reasons why. Start with the float — with less than 1.5 million shares available to the public, ONCO's tiny share count means even modest demand could translate into outsized price moves. Then there's the humanoid robotics angle: through its pending acquisition of Realbotix, ONCO is stepping directly into the AI-powered humanoid robot space, targeting consumer-facing applications across customer service, healthcare, education, hospitality, and entertainment. On the diagnostics side, the company's Proclarix® blood test is now being evaluated in the U.S. through the PRIME study alongside Labcorp, targeting up to 500 participants across multiple sites.
That Realbotix deal is also working toward a defined finish line, with a transaction expected to close by October 2026 that would bring Realbotix's humanoid robotics operations onto Nasdaq. Realbotix itself already has a marquee enterprise relationship in place, having delivered its first Vinci-equipped humanoid robot to Ericsson. On the clinical side, ONCO recently pointed to two new peer-reviewed studies backing Proclarix®'s diagnostic and prognostic value in prostate cancer patients. And the company isn't pre-revenue on the diagnostics front either — Proclarix® already has an active commercial footprint across Europe, including a real-world screening initiative in the United Kingdom. Put it all together — a microscopic float, a live U.S. diagnostics validation program, and a pending Nasdaq-bound AI robotics deal backed by a company that counts a global telecom giant as its first customer — and it's easy to see why ONCO is topping watchlists today.
Onconetix holds a license agreement with Labcorp Holdings Inc. to develop and commercialize Proclarix® in the United States as a lab-developed test, which is the company's chosen route into the domestic market. In February 2026, Onconetix entered into a definitive share exchange agreement to acquire 100% of Realbotix LLC, a Nevada-based subsidiary of Realbotix Corp. that designs and manufactures AI-powered humanoid robots for social and commercial applications, with operations spanning an engineering division, an AI software division, and a growing base of robotics patents and intellectual property. Under the all-stock deal structure, Realbotix's parent is expected to own between 75% and 90% of the combined company at closing, with the exact split tied to Onconetix's net cash position at the time, and the combined company is expected to trade on Nasdaq following a close anticipated in the second half of 2026, with an October target, pending ONCO shareholder approval and regulatory clearances. On the leadership front, David White was appointed CEO effective March 18, 2026, and Sammy Dorf joined the board effective March 19, 2026, as the company builds out the team needed to execute the Realbotix transaction and drive its next phase of growth.
What makes Onconetix an unusual story is that it sits at the intersection of two structurally significant themes: precision oncology diagnostics and embodied artificial intelligence. Prostate cancer remains the most frequently diagnosed male cancer globally, and the real clinical challenge has never been detection — PSA testing is already widespread — but rather distinguishing tumors that need treatment from those that don't. Overdiagnosis and the resulting wave of unnecessary biopsies remain a costly, recognized problem across healthcare systems worldwide, which is exactly where blood-based diagnostics like Proclarix® come in, offering a more accurate way to stratify risk. The global prostate cancer diagnostics market continues to expand as populations age and awareness grows that early risk stratification both improves outcomes and lowers overall care costs. More broadly, the in-vitro diagnostics industry is shifting toward protein-based blood tests and liquid biopsy platforms that deliver clinical insight without invasive procedures, and regulatory frameworks in both the EU and U.S. have been evolving to support that shift. Onconetix's strategy — securing CE certification in Europe first, then pursuing LDT commercialization in the U.S. through Labcorp — is a capital-efficient path that sidesteps the cost and timeline of a full standalone PMA submission while still targeting one of the largest diagnostics markets in the world.
On the robotics side, humanoid AI is moving from demonstration to real-world deployment faster than most expected. Enterprise players like Ericsson are already integrating humanoid robots into live connectivity trials and commercial environments, and the broader market for service-oriented humanoid robots in healthcare, hospitality, education, and retail — while still early — is drawing serious attention from both enterprise buyers and capital markets. Realbotix's position at the front of that curve is underscored by Ericsson as its first enterprise client, with Realbotix robots already featured in a world-first 6G trial. This combination places Onconetix in a rare position: part clinical diagnostics operator, part potential AI-robotics gateway, with markets now watching how — and if — these two narratives converge into a cohesive long-term strategy.
There's also been a steady stream of recent milestones supporting the story. Proteomedix AG, in collaboration with Labcorp, officially launched the PRIME study, a multi-center U.S. clinical validation trial for Proclarix® that has already enrolled its first participants as part of Onconetix's broader LDT commercialization push. On the clinical data front, Onconetix reported two new peer-reviewed publications from a Danish clinical cohort — one study of 371 men showed Proclarix® outperforming %fPSA and the ERSPC risk calculator in ruling out clinically insignificant prostate cancer and reducing unnecessary biopsies, while a second study of 132 men under active surveillance demonstrated Proclarix®'s ability to help predict the transition from monitoring to active treatment.
On the commercial side, Realbotix delivered its first Vinci-equipped humanoid robot to Ericsson — Vinci being Realbotix's patented AI vision system that gives robots real-time environmental awareness through in-eye cameras, including user recognition, eye contact, conversation recall, and behavioral data collection. That same technology was put on display when a Realbotix humanoid robot served as a live robotics endpoint in Ericsson's pre-standard 6G over-the-air trial at Ericsson's U.S. headquarters in Plano, Texas, streaming video and interacting in real time over Ericsson's test network.
Realbotix has also expanded into education, launching Optio — its AI-powered teacher's assistant and at-home tutor — in a pilot program at Salamanca City Central School District on the Seneca Nation Reservation in New York. Optio pairs students with personalized, curriculum-trained avatars that deliver tutoring, concept reinforcement, and 24/7 homework support in multiple languages, all under district oversight and built-in safety guardrails, with added support for neurodiverse learners; the district, a recognized Woz ED STEM Pathway district, will use Optio to support its high school AI and Robotics courses, alongside a deployed Realbotix M-Series humanoid robot that brings natural conversation and real-time interaction into the classroom. Meanwhile, Onconetix's European footprint continues to grow — in the United Kingdom, Proclarix® is now offered through a patient organization as part of a real-world prostate cancer screening initiative that administered close to 100 tests in Q1 2026 alone, and the company has also identified a new commercial collaboration partner in Turkey as it works to expand access across additional European markets.
NEWS
Onconetix, Inc. Announces 1-for-10 Reverse Stock SplitGlobeNewswire - Tue May 19, 7:00AM CDTCINCINNATI, Ohio, May 19, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ: ONCO) (“Onconetix” or the “Company”), a commercial-stage biotechnology company focused on the research, development,...
Onconetix Reports Q1 2026 Progress at Proteomedix AG, Including Two New Peer-Reviewed Publications and Initiation of U.S. Validation StudyGlobeNewswire - Wed May 13, 8:25AM CDTNew Clinical Data Reinforce Proclarix® Performance in Reducing Overdiagnosis and Unnecessary Biopsies; Multi-Center PRIME Study Initiated in Collaboration with Labcorp; European Commercial Expansion Advances...
Onconetix Highlights Realbotix's Launch of Vinci AI Vision System with Delivery of First Vinci-Equipped Humanoid Robot to EricssonGlobeNewswire - Thu Apr 9, 7:30AM CDTVinci Enables Realbotix Robots to Recognize People, Recall Conversations, and Track Engagement; Onconetix Recently Entered into a Definitive Agreement to Acquire Realbotix LLC, a Subsidiary of Realbotix...
Onconetix Highlights Realbotix AI Humanoid Robot Delivery UpdateGlobeNewswire - Thu Apr 2, 7:30AM CDTRealbotix Announces Expected Delivery of 19 Robots in March, April, and May 2026 as it Scales Production Capacity; Onconetix recently Entered into a Definitive Agreement to Acquire Realbotix LLC, a subsidiary...
MANAGEMENT
David Allan White
Chief Executive Officer
David Allan White has been the Chief Executive Officer since March 2026. Mr. White is an Independent Director with more than 30 years of executive leadership and board experience, having served in senior roles including Chief Executive Officer, Chief Financial Officer, and Chief Operating Officer. He served as an independent director and Chair of the Audit Committee of SRx Holdings, Inc. (NYSE American: SRXH) from February 2025 to October 2025. He also served as an independent director and Chair of the Audit Committee of AG Growth International, Inc., a TSX-listed global equipment manufacturer from November 2006 to May 2025. Mr. White is currently an independent director of Art’s Way Manufacturing, Inc., a NASDAQ-listed equipment manufacturer, where he is also the chairman of their compensation committee and a member on the audit committee. He was also an independent director of Patient Care Logistics Solutions, a private equity-sponsored passenger transportation and patient care logistics company, from March 2018 to December 2025. Earlier in his career, Mr. White served as President and Chief Executive Officer of Student Transportation Partners from April 2021 to May 2023, where he led the formation of the management team and established the company’s strategic vision, before transitioning to its Board of Directors in May 2023. He also served as Chief Executive Officer of TransCare Inc. from 2008 to 2012, a New York-based ambulance company providing emergency medical response services and transit operations across multiple major U.S. cities. Mr. White previously held senior leadership roles at Laidlaw Inc., where he served as Chief Financial Officer of the Passenger Services Group and Regional General Manager for Western Canadian operations from 1991 to 1993 before becoming President of the company’s Ambulance division in 1993. He also served as President and Chief Operating Officer of Student Transportation of America during a period of significant growth following its public offering from May 2021 to August 2025. Mr. White began his career as a financial executive with Coopers & Lybrand in 1975 and held roles with several Fortune 1000 companies, including John Labatt Limited and Lawson Mardon. He holds a Bachelor of Arts from the University of Western Ontario and a Master of Business Administration from the University of Toronto, and is a Chartered Professional Accountant (CPA, CA) and ICD.D designee.
Karina M. Fedasz
Interim Chief Financial Officer
Karina M. Fedasz has been the Interim Chief Financial Officer since June 2024. For more than two decades, Ms. Fedasz has helped companies raise capital, model and forecast business, manage cash flow and conduct mergers and acquisitions. She is a dynamic, data-driven executive with a bold, high-growth mindset. From January 2023 to June 2024, Ms. Fedasz worked with various clients, including a not-for-profit and an early-stage artificial intelligence and data-driven health and wellness tracker. From February 2022 to December 2022, Ms. Fedasz served as Head of Business Development for Evofem Biosciences, a Nasdaq-listed public biotech company developing innovative products for women's health. From August 2019 to October 2021, Ms. Fedasz served in various positions of increasing responsibility, including Chief Financial Officer, at IDW Media Holdings, a micro-cap media company, where she managed the company's initial public offering. From April 2018 to August 2019, Ms. Fedasz served as Chief Financial Officer of MOCEAN, an integrated agency for entertainment, gaming, and brands. Ms. Fedasz's breadth of experience has seen her lead teams in media, technology, services, manufacturing, and education, and she has worked with companies whose clients and customers include Fortune 500 companies such as Netflix, Disney, Amazon, Apple, Activision, and EA. Ms. Fedasz received an MBA with an emphasis in finance from Columbia Business School and a BA from University California at Los Angeles (UCLA). She holds an inactive CPA in the state of California.
DISCLAIMER
THIS WEBSITE/NEWSLETTER IS A PUBLICATION OF ONE22 MEDIA, LLC, HEREIN REFERRED TO AS O22. O22’S REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATIONAL PURPOSES ONLY.O22 IS ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION.
O22 HAS BEEN COMPENSATED A FEE OF FIFTEEN THOUSAND USD DIRECTLY BY A THIRD PARTY, TD MEDIA, LLC FOR A ONE DAY ONCO PROFILE ON 7/6/26.
BY SUBSCRIBING TO OR OTHERWISE USING THIS WEBSITE/NEWSLETTER, YOU AGREE TO HOLD O22 AND ITS OPERATORS, OWNERS, AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS, DAMAGE, OR INJURY THAT YOU MAY INCUR, MONETARY OR OTHERWISE.
INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AN EXTREMELY HIGH DEGREE OF RISK. NEVER INVEST IN ANY STOCK FEATURED ON O22’S SITE OR NEWSLETTER UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING O22’S SERVICES, JOINING O22’S SITE OR EMAIL/BLOG LIST, OR FOLLOWING ANY SOCIAL NETWORKING PLATFORMS O22 MAY USE.
PLEASE NOTE WELL: O22 IS NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER. O22 IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES AND EXCHANGE COMMISSION, OR FINRA. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED.
THE INFORMATION CONTAINED HEREIN IS BASED ON INFORMATION SUPPLIED BY THE COMPANIES PROFILED, PUBLICLY AVAILABLE INFORMATION, PRESS RELEASES, AND OTHER SOURCES WHICH O22 BELIEVES TO BE RELIABLE, BUT IS NOT GUARANTEED BY O22 AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. O22 IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES PROFILED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE/NEWSLETTER IN DECIDING TO INVEST OR MAKE OTHER FINANCIAL DECISIONS. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE/NEWSLETTER AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. O22 STRONGLY ENCOURAGES READERS AND INVESTORS TO CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES, INCLUDING BY REVIEWING SEC FILINGS (FORMS 10-Q, 10-K, 8-K, 3, 4, 5, SCHEDULE 13D) AND BY CONSULTING YOUR OWN TAX, BUSINESS, FINANCIAL, AND INVESTMENT ADVISORS.
THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT, AND MAY BE FORWARD-LOOKING STATEMENTS. FORWARD-LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD-LOOKING STATEMENTS MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEES, EXPECTS, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, MAY, COULD, OR MIGHT. THERE IS NO GUARANTEE THAT PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS.